Induction of epithelial-mesenchymal transition via activation of epidermal growth factor receptor contributes to sunitinib resistance in human renal cell carcinoma cell lines

Journal of Pharmacology and Experimental Therapeutics

Volumn 355, Issue 2, 2015, Pages 152-158

  Mizumoto, Atsushi ^a   Yamamoto, Kazuhiro ^b   Nakayama, Yuko ^c   Takara, Kohji ^c   Nakagawa, Tsutomu ^a,b   Hirano, Takeshi ^a,b   Hirai, Midori ^a,b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY HOSPITAL   (Japan)

^c HIMEJI DOKKYO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; CARCINOMA, RENAL CELL; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; KIDNEY NEOPLASMS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; INDOLES; KIDNEY NEOPLASMS; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84946557453     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.226639     Document Type: Article

References (42)

1. Abouantoun TJ, Castellino RC, and MacDonald TJ (2011) Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells. J Neurooncol 101:215-226.
2. Bae GY, Choi SJ, Lee JS, Jo J, Lee J, Kim J, and Cha HJ (2013) Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer. Oncotarget 4:2512-2522.
3. Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, Kearsley JH, and Li Y (2013) Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis 4:e875.
4. Dai H, Song D, Xu J, Li B, Hertz L, and Peng L (2013) Ammonia-induced Na, K-ATPase/ouabain-mediated EGF receptor transactivation, MAPK/ERK and PI3K/AKT signaling and ROS formation cause astrocyte swelling. Neurochem Int 63:610-625.
5. Ding G, Zhang A, Huang S, Pan X, Zhen G, Chen R, and Yang T (2007) ANG II induces c-Jun NH2-terminal kinase activation and proliferation of human mesangial cells via redox-sensitive transactivation of the EGFR. Am J Physiol Renal Physiol 293:F1889-F1897.
6. Dong P, Konno Y, Watari H, Hosaka M, Noguchi M, and Sakuragi N (2014) The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer. J Transl Med 12:231.
7. Dordević G, Matušan Ilijaš K, Hadžisejdić I, Maričić A, Grahovac B, and Jonjić N (2012) EGFR protein overexpression correlates with chromosome 7 polysomy and poor prognostic parameters in clear cell renal cell carcinoma. J Biomed Sci 19:40.
8. Durán M, Matheus W, Ferreira U, and Clark O (2013) Systematic review and metaanalysis of target terapies for the treatment of metastatic renal cancer. Int Braz J Urol 39:768-778.
9. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, and Christensen J, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
10. Faivre S, Demetri G, Sargent W, and Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734-745.
11. Flaig TW, Costa LJ, Gustafson DL, Breaker K, Schultz MK, Crighton F, Kim FJ, and Drabkin H (2010) Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. Br J Cancer 103:796-801.
12. Holland WS, Tepper CG, Pietri JE, Chinn DC, Gandara DR, Mack PC, and Lara PN Jr (2012) Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. Cancer Chemother Pharmacol 69:185-194.
13. Hollier BG, Evans K, and Mani SA (2009) The epithelial-to-mesenchymal transition and cancer stem cells: A coalition against cancer therapies. J Mammary Gland Biol Neoplasia 14:29-43.
14. Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, and Teh BT (2010) Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70:1053-1062.
15. Huber MA, Kraut N, and Beug H (2005) Molecular requirements for epithelialmesenchymal transition during tumor progression. Curr Opin Cell Biol 17:548-558.
16. Ishimaru T, Lau J, Jackson AL, Modiano JF, and Weiss RH (2010) Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma. J Urol 184:2143-2149.
17. Katoh M and Katoh M (2006) Cross-talk of WNT and FGF signaling pathways at GSK3beta to regulate beta-catenin and SNAIL signaling cascades. Cancer Biol Ther 5:1059-1064.
18. Keitel U, Scheel C, and Dobbelstein M (2014) Overcoming EMT-driven therapeutic resistance by BH3 mimetics. Oncoscience 1:706-708.
19. Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, and Belldegrun AS (2007) Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 13:7388-7393.
20. Lappano R and Maggiolini M (2011) G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 10:47-60.
21. Leung HW, Chan AL, and Lin SJ (2014) Indirect comparisons of efficacy and safety between seven newer targeted agents for metastatic renal cell carcinoma: A network meta-analysis of randomised clinical trials. Mol Clin Oncol 2:858-864.
22. Maillé E, Trinh NT, Privé A, Bilodeau C, Bissonnette E, Grandvaux N, and Brochiero E (2011) Regulation of normal and cystic fibrosis airway epithelial repair processes by TNF-a after injury. Am J Physiol Lung Cell Mol Physiol 301:L945-L955.
23. Makhov PB, Golovine K, Kutikov A, Teper E, Canter DJ, Simhan J, Uzzo RG, and Kolenko VM (2012) Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther 11:1510-1517.
24. Moch H, Sauter G, Buchholz N, Gasser TC, Bubendorf L, Waldman FM, and Mihatsch MJ (1997) Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Hum Pathol 28:1255-1259.
25. Moreno-Càceres J, Caja L, Mainez J, Mayoral R, Martín-Sanz P, Moreno-Vicente R, Del Pozo MÁ, Dooley S, Egea G, and Fabregat I (2014) Caveolin-1 is required for TGF-b-induced transactivation of the EGF receptor pathway in hepatocytes through the activation of the metalloprotease TACE/ADAM17. Cell Death Dis 5:e1326.
26. Muriel López C, Esteban E, Astudillo A, Pardo P, Berros JP, Izquierdo M, Crespo G, Fonseca PJ, Sanmamed M, and Martínez-Camblor P (2012) Predictive factors for response to treatment in patients with advanced renal cell carcinoma. Invest New Drugs 30:2443-2449.
27. Paoli P, Giannoni E, and Chiarugi P (2013) Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta 1833:3481-3498.
28. Roskoski R Jr (2007) Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 356:323-328.
29. Sánchez-Tilló E, Siles L, de Barrios O, Cuatrecasas M, Vaquero EC, Castells A, and Postigo A (2011) Expanding roles of ZEB factors in tumorigenesis and tumor progression. Am J Cancer Res 1:897-912.
30. Santamaria PG and Nebreda AR (2010) Deconstructing ERK signaling in tumorigenesis. Mol Cell 38:3-5.
31. Shinojima T, Oya M, Takayanagi A, Mizuno R, Shimizu N, and Murai M (2007) Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. Carcinogenesis 28:529-536.
32. Shorning BY, Griffiths D, and Clarke AR (2011) Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder. PLoS One 6:e16209.
33. Sorkin A (2001) Internalization of the epidermal growth factor receptor: role in signalling. Biochem Soc Trans 29:480-484.
34. Stickle NH, Cheng LS, Watson IR, Alon N, Malkin D, Irwin MS, and Ohh M (2005) Expression of p53 in renal carcinoma cells is independent of pVHL. Mutat Res 578: 23-32.
35. Uemura H, Shinohara N, Yuasa T, Tomita Y, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Nonomura N, and Takahashi M, et al. (2010) A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 40:194-202.
36. Voon DC, Wang H, Koo JK, Chai JH, Hor YT, Tan TZ, Chu YS, Mori S, and Ito Y (2013) EMT-induced stemness and tumorigenicity are fueled by the EGFR/Ras pathway. PLoS One 8:e70427.
37. Wang Y, Roche O, Yan MS, Finak G, Evans AJ, Metcalf JL, Hast BE, Hanna SC, Wondergem B, and Furge KA, et al. (2009) Regulation of endocytosis via the oxygen-sensing pathway. Nat Med 15:319-324.
38. Weygant N, Qu D, May R, Tierney RM, Berry WL, Zhao L, Agarwal S, Chandrakesan P, Chinthalapally HR, and Murphy NT, et al. (2015) DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma. Oncotarget 6:2193-2205.
39. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, and Sugita M, et al. (2006) Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66:944-950.
40. Yamamoto K, Mizumoto A, Nishimura K, Uda A, Mukai A, Yamashita K, Kume M, Makimoto H, Bito T, and Nishigori C, et al. (2014) Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3). PLoS One 9:e102110.
41. Yang J, Ikezoe T, Nishioka C, Takezaki Y, Hanazaki K, Taguchi T, and Yokoyama A (2012) Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene. Int J Cancer 130:959-966.
42. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, and Rho JK, et al. (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44:852-860.